NEPHROSTERIL

Indications

• Paracetamol overdose
• Chronic obstructive pulmonary disease (COPD)
• Cystic fibrosis
• Bronchiectasis
• Mucolytic therapy for excessive mucus production

Dosage

Children: For paracetamol overdose in children, the initial dose is 150 mg/kg IV over 15 minutes, followed by 50 mg/kg IV over 4 hours, and then 100 mg/kg IV over 16 hours. Refer to BNF for Children for detailed dosing.

Adults: For paracetamol overdose, the initial dose is 300 mg IV over 15 minutes, followed by 600 mg IV over 4 hours, and then 1200 mg IV over 16 hours. Refer to specific guidelines for other indications.

Mechanism of action

Acetylcysteine works by breaking disulfide bonds in mucoproteins, leading to the depolymerization of mucus and reducing its viscosity, making it easier to clear from the airways.

Pharmacodynamics

Acetylcysteine enhances mucociliary clearance and helps restore depleted glutathione levels, which is critical in the detoxification of harmful substances in the liver, particularly in cases of paracetamol toxicity.

Pharmacokinetics

When administered orally, acetylcysteine is rapidly absorbed and metabolized in the liver. It has a half-life of approximately 1 to 2 hours, with its effects lasting longer due to its metabolites. The major route of excretion is via the urine.

Contra-indications

• Severe asthma
• History of peptic ulceration

Adverse effects

• Nausea
• Vomiting
• Abdominal pain
• Diarrhea
• Skin rashes
• Anaphylactic reactions

Interactions

• May increase INR in patients on anticoagulants

Precautions

• Use with caution in patients with asthma
• Monitor for allergic reactions

Pregnancy

Use only if clearly needed; benefits must outweigh risks.

Breast-feeding

Considered safe; minimal transfer into breast milk.

Storage

Store in a cool, dry place away from light.

Formulations

• Oral solution
• Injectable solution

Indications

• Bladder irrigation during urological surgery
• Irrigation for transurethral resection of the prostate gland
• Irrigation for bladder tumors

Dosage

Children: Refer to the BNF for Children for pediatric dosing guidelines.

Adults: Refer to the product literature for specific dosing information.

Mechanism of action

Glycine binds to strychnine-sensitive and strychnine-insensitive glycine receptors in the central nervous system. The strychnine-sensitive receptor is a chloride channel that enhances inhibitory neurotransmission. This action may contribute to glycine's potential antispastic effects. Additionally, glycine potentiates NMDA receptor-mediated neurotransmission, which may have implications in managing certain neurological conditions, such as neuroleptic-resistant negative symptoms in schizophrenia.

Pharmacodynamics

Glycine plays a crucial role in various biological functions, including energy metabolism and immune response. It is involved in hormone synthesis and helps in modulating neurotransmitter release, particularly in inhibitory pathways. Glycine's ability to enhance chloride conductance in neurons contributes to its antispastic properties and its potential to mitigate oxidative stress in immune responses.

Pharmacokinetics

Glycine is absorbed readily in the gastrointestinal tract and is utilized by the body for protein synthesis and other metabolic functions. The distribution of glycine in the body is widespread, as it is present in various tissues. Glycine is metabolized in the liver and other tissues, with excretion primarily occurring via the kidneys. The pharmacokinetics of glycine can be influenced by factors such as age, renal function, and overall health status.

Adverse effects

• Fluid overload
• Electrolyte imbalance
• Nausea
• Vomiting
• Headache
• Hypotension

Precautions

• Monitor for signs of fluid overload during irrigation
• Use caution in patients with pre-existing electrolyte imbalances
• Careful consideration in patients with renal impairment

Pregnancy

Glycine is generally considered safe for use during pregnancy when used as an irrigation solution, but risks should be discussed with a healthcare provider.

Breast-feeding

Glycine is likely safe during breastfeeding, but limited data is available. Consultation with a healthcare professional is advisable.

Storage

Store in a cool, dry place. Protect from light. Do not freeze.

Formulations

• Glycine 1.5% irrigation solution 3 litre Easyflow bags
• Glycine 1.5% irrigation solution 1 litre Flowfusor bottles
• Glycine 1.5% irrigation solution 1 litre Easyflow bags
• Glycine 1.5% irrigation solution 2 litre Flowfusor bottles

Indications

• Cancer (various types)
• Rheumatoid arthritis
• Multiple sclerosis
• Inflammatory bowel disease
• Psoriasis
• Hypercholesterolemia
• Infectious diseases (e.g., COVID-19)

Dosage

Children: Refer to the BNF for Children for paediatric dosing information, as it varies based on the specific monoclonal antibody and the condition being treated.

Adults: Refer to the specific monoclonal antibody product information for adult dosage, as it varies based on indication and specific agent used.

Mechanism of action

Monoclonal antibodies work by binding to specific proteins on the surface of cells. This binding can block the activity of certain proteins, mark cells for destruction by the immune system, or deliver cytotoxic agents directly to target cells. The mechanism of action varies depending on the specific monoclonal antibody but often involves modulation of immune response, inhibition of cell proliferation, and induction of apoptotic pathways.

Pharmacodynamics

The pharmacodynamics of monoclonal antibodies is primarily characterized by their specificity and affinity for targeted antigens. This leads to a variety of effects, including neutralization of pathogens, blockade of receptor-ligand interactions, and antibody-dependent cellular cytotoxicity. The clinical effects depend on the disease being treated and the specific antibody's action, such as inducing tumor regression in cancer or reducing inflammation in autoimmune diseases.

Pharmacokinetics

Monoclonal antibodies typically have a long half-life, allowing for less frequent dosing. They are generally administered intravenously or subcutaneously, with absorption and distribution influenced by the antibody's size and charge. The elimination occurs primarily through proteolytic degradation and intracellular recycling. Factors such as patient-specific variables, including immunogenicity and the presence of antibodies against the monoclonal antibody, can impact pharmacokinetics.

Interactions

• abatacept+monoclonalantibodies: Severe (increases risk of generalised infection (possibly life-threatening))
• anakinra+monoclonalantibodies: Severe (increases risk of generalised infection (possibly life-threatening))
• anthracyclines+monoclonalantibodies: Severe (increases risk of cardiotoxicity)
• filgotinib+monoclonalantibodies: Severe (increases risk of immunosuppression)
• monoclonalantibodies+fingolimod: Severe (increases risk of generalised infection (possibly life-threatening))
• normal immunoglobulin+monoclonalantibodies: Severe (affects effects)
• monoclonalantibodies+ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• monoclonalantibodies+siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• monoclonalantibodies+vemurafenib: Severe (increases risk of hepatotoxicity)
• monoclonalantibodies+aminophylline: Moderate (decreases exposure)

Mechanism of action

Monoacetate acts primarily as a substrate in cellular metabolism, participating in pathways that involve the conversion of NAD to NADH and NADP to NADPH. This interconversion is vital for maintaining the redox balance in cells, facilitating energy production and biosynthetic reactions.

Pharmacodynamics

The pharmacodynamic properties of monoacetate are linked to its role in energy metabolism and biosynthetic pathways. It contributes to the generation of reducing equivalents (NADH and NADPH), which are essential for various anabolic processes, including fatty acid synthesis and nucleotide biosynthesis. The modulation of these pathways can influence cellular energy status and metabolic health.

Pharmacokinetics

Monoacetate is rapidly absorbed and metabolized in the body. Its distribution may vary based on the specific cellular demands for energy and reducing equivalents. The elimination of monoacetate is primarily through metabolic conversion to other compounds involved in the Krebs cycle and other metabolic pathways.

Pregnancy

There is limited data on the effects of monoacetate during pregnancy. Consult relevant guidelines and consider the risks versus benefits.

Breast-feeding

Limited data available on the excretion of monoacetate in breast milk. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Mechanism of action

A number of possible mechanisms for the mucolytic activity of acetylcysteine have been proposed. Acetylcysteine's sulfhydryl groups may hydrolize disulfide bonds within mucin, breaking down the oligomers, and making the mucin less viscous. Acetylcysteine has also been shown to reduce mucin secretion in rat models. It is an antioxidant in its own right but is also deacetylated to cysteine, which participates in the synthesis of the antioxidant glutathione. The antioxidant activity may also alter intracellular redox reactions, decreasing phosphorylation of EGFR and MAPK, which decrease transcription of the gene MUC5AC which produces mucin. In the case of acetaminophen overdoses, a portion of the drug is metabolized by CYP2E1 to form the potentially toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). The amount of NAPQI produced in an overdose saturates and depletes glutathione stores. The free NAPQI promiscuously binds to proteins in hepatocytes, leading to cellular necrosis. Acetylcysteine can directly conjugate NAPQI or provide cysteine for glutathione production and NAPQI conjugation. Acetylcysteine exerts its mucolytic action through its free sulfhydryl group, which opens the disulfide bonds and lower the viscosity of the mucus. This action increases with increasing pH and is most significant at pH 7 to 9. The mucolytic action of acetylcysteine is not affected by the presence of DNA. Acetylcysteine may protect against acetaminophen overdose-induced hepatotoxicity by maintaining or restoring hepatic concentrations of glutathione. Glutathione is required to inactivate an intermediate metabolite of acetaminophen that is thought to be hepatotoxic. In acetaminophen overdose, excessive quantities of this metabolite are formed because the primary metabolic (glucuronide and sulfate conjugation) pathways become saturated. Acetylcysteine may act by reducing the metabolite to the parent compound and/or by providing sulfhydryl for conjugation of the metabolite. Experimental evidence also suggests that a sulfhydryl-containing compound such as acetylcysteine may directly inactivate the metabolite.

Pharmacodynamics

Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose. It has a short duration of action as it is given every 1-8 hours depending on route of administration, and has a wide therapeutic window. Patients should be counselled regarding diluting oral solutions in cola for taste masking, the risk of hypersensitivity, and the risk of upper gastrointestinal hemorrhage.

Mechanism of action

In the CNS, there exist strychnine-sensitive glycine binding sites as well as strychnine-insensitive glycine binding sites. The strychnine-insensitive glycine-binding site is located on the NMDA receptor complex. The strychnine-sensitive glycine receptor complex is comprised of a chloride channel and is a member of the ligand-gated ion channel superfamily. The putative antispastic activity of supplemental glycine could be mediated by glycine's binding to strychnine-sensitive binding sites in the spinal cord. This would result in increased chloride conductance and consequent enhancement of inhibitory neurotransmission. The ability of glycine to potentiate NMDA receptor-mediated neurotransmission raised the possibility of its use in the management of neuroleptic-resistant negative symptoms in schizophrenia. Animal studies indicate that supplemental glycine protects against endotoxin-induced lethality, hypoxia-reperfusion injury after liver transplantation, and D-galactosamine-mediated liver injury. Neutrophils are thought to participate in these pathologic processes via invasion of tissue and releasing such reactive oxygen species as superoxide. In vitro studies have shown that neutrophils contain a glycine-gated chloride channel that can attenuate increases in intracellular calcium and diminsh neutrophil oxidant production. This research is ealy-stage, but suggests that supplementary glycine may turn out to be useful in processes where neutrophil infiltration contributes to toxicity, such as ARDS. HYPERPOLARIZATION OF MOTONEURONS PRODUCED BY IONTOPHORETIC APPLICATION OF GLYCINE IS RELATIVELY TRANSIENT BUT APPROACHES THE EQUILIBRIUM POTENTIAL FOR THE INDIRECTLY ACTIVATED INHIBITORY POSTSYNAPTIC POTENTIAL...TESTS WITH GABA... INDICATE SIMILAR ELECTROPHYSIOLOGICAL EFFECTS & SIMILAR INCR IN CL- CONDUCTANCE. MAJOR EVIDENCE THAT FAVORS GLYCINE AS MEDIATOR OF INTRASPINAL POSTSYNAPTIC INHIBITION IS THE SELECTIVE ANTAGONISM OF ITS EFFECTS BY STRYCHNINE. ... GLYCINE ALSO APPEARS TO BE MOST LIKELY TRANSMITTER FOR INHIBITORY INTERNEURONS IN RETICULAR FORMATION BUT NOT IN CUNEATE NUCLEUS.

Pharmacodynamics

Helps trigger the release of oxygen to the energy requiring cell-making process; Important in the manufacturing of hormones responsible for a strong immune system.